Akabani G - Search Results

1

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. Larsen RH, et al. Among authors: akabani g. J Nucl Med. 1999 Jul;40(7):1197-203. J Nucl Med. 1999. PMID: 10405142 Free article.

2

Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.

Akabani G, Kennel SJ, Zalutsky MR. Akabani G, et al. J Nucl Med. 2003 May;44(5):792-805. J Nucl Med. 2003. PMID: 12732682 Free article.

3

In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.

Carlin S, Akabani G, Zalutsky MR. Carlin S, et al. Among authors: akabani g. J Nucl Med. 2003 Nov;44(11):1827-38. J Nucl Med. 2003. PMID: 14602867 Free article.

4

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Zalutsky MR, et al. Among authors: akabani g. J Nucl Med. 2008 Jan;49(1):30-8. doi: 10.2967/jnumed.107.046938. Epub 2007 Dec 12. J Nucl Med. 2008. PMID: 18077533 Free PMC article.

5

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman RE, Zhao XG, Bigner DD, Zalutsky MR. Akabani G, et al. J Nucl Med. 1999 Apr;40(4):631-8. J Nucl Med. 1999. PMID: 10210222 Free article. Clinical Trial.

6

Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.

Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. Aurlien E, et al. Among authors: akabani g. Int J Radiat Biol. 2000 Aug;76(8):1129-41. doi: 10.1080/09553000050111604. Int J Radiat Biol. 2000. PMID: 10947126

7

Microdosimetry of astatine-211 using histological images: application to bone marrow.

Akabani G, Zalutsky MR. Akabani G, et al. Radiat Res. 1997 Dec;148(6):599-607. Radiat Res. 1997. PMID: 9399706

8

Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.

Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Boskovitz A, et al. Nucl Med Biol. 2004 Apr;31(3):345-55. doi: 10.1016/j.nucmedbio.2003.10.008. Nucl Med Biol. 2004. PMID: 15028247

9

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR. Akabani G, et al. J Nucl Med. 2005 Jun;46(6):1042-51. J Nucl Med. 2005. PMID: 15937318 Free article. Clinical Trial.

10

In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

Akabani G, Carlin S, Welsh P, Zalutsky MR. Akabani G, et al. Nucl Med Biol. 2006 Apr;33(3):333-47. doi: 10.1016/j.nucmedbio.2005.12.006. Epub 2006 Mar 9. Nucl Med Biol. 2006. PMID: 16631082

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page